Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine

We present a case of acute bilateral multifocal CSCR in a young healthy Caucasian female occurring 3 days after receiving the first dose of the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. The true incidence of this adverse reaction might be underreported in asymptomatic unilateral or paracentral...

Descripción completa

Detalles Bibliográficos
Autores principales: Mechleb, N., Khoueir, Z., Assi, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046098/
https://www.ncbi.nlm.nih.gov/pubmed/35599048
http://dx.doi.org/10.1016/j.jfo.2022.02.001
_version_ 1784695450912161792
author Mechleb, N.
Khoueir, Z.
Assi, A.
author_facet Mechleb, N.
Khoueir, Z.
Assi, A.
author_sort Mechleb, N.
collection PubMed
description We present a case of acute bilateral multifocal CSCR in a young healthy Caucasian female occurring 3 days after receiving the first dose of the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. The true incidence of this adverse reaction might be underreported in asymptomatic unilateral or paracentral cases. We believe that the post-COVID-19 vaccination occurrence of CSCR is not a sufficient reason to withhold the second dose of the vaccine. Further studies are required to ascertain the best way to prevent and manage this complication.
format Online
Article
Text
id pubmed-9046098
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-90460982022-04-28 Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine Mechleb, N. Khoueir, Z. Assi, A. J Fr Ophtalmol Original Article We present a case of acute bilateral multifocal CSCR in a young healthy Caucasian female occurring 3 days after receiving the first dose of the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. The true incidence of this adverse reaction might be underreported in asymptomatic unilateral or paracentral cases. We believe that the post-COVID-19 vaccination occurrence of CSCR is not a sufficient reason to withhold the second dose of the vaccine. Further studies are required to ascertain the best way to prevent and manage this complication. Elsevier Masson SAS. 2022-06 2022-04-28 /pmc/articles/PMC9046098/ /pubmed/35599048 http://dx.doi.org/10.1016/j.jfo.2022.02.001 Text en © 2022 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Mechleb, N.
Khoueir, Z.
Assi, A.
Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine
title Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine
title_full Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine
title_fullStr Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine
title_full_unstemmed Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine
title_short Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine
title_sort bilateral multifocal central serous retinopathy following mrna covid-19 vaccine
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046098/
https://www.ncbi.nlm.nih.gov/pubmed/35599048
http://dx.doi.org/10.1016/j.jfo.2022.02.001
work_keys_str_mv AT mechlebn bilateralmultifocalcentralserousretinopathyfollowingmrnacovid19vaccine
AT khoueirz bilateralmultifocalcentralserousretinopathyfollowingmrnacovid19vaccine
AT assia bilateralmultifocalcentralserousretinopathyfollowingmrnacovid19vaccine

Ejemplares similares